Nitza founded her consulting company, NtzConsulting, in 2018. She represents Omnes Capital at Antabio’s board of directors. Nitza is the co-founder of Gensight Biologics (Gene therapy for ophthalmologic diseases) and BrainEver (Advanced medicinal products to treat neurodegenerative diseases). After a post doc at Northwestern & Rush University (Chicago, USA), she joined the pharma industry to develop medicines for neurologic and psychiatric disorders at Servier. Then she moved to the biotech world, joining Fovea Pharma in 2009, that became Ophthalmology Division of Sanofi. She contributed to the start of Tissium, while co-founding GenSight Biologics, then BrainEver. Her salient skill remains the translation of transformative technology/science into human innovative therapeutics addressing unmet medical needs.